文档介绍：Procedure:
Activated Clotting Time (ACT+) Test
Hemochron® Signature+
Hemochron Signature Elite®
Approved by ________________________________ Date _______________
Created by ________________________________ Date ________________
Reviewed by ________________________________ Date ________________
Reviewed by ________________________________ Date _________________
Reviewed by ________________________________ Date _________________
Reviewed by ________________________________ Date _________________
Contact Person(s) __________________________________________________
Contact Number(s) _________________________________________________
Purpose
The Hemochron® Jr. Activated Clotting Time Plus (ACT+) is a quantitative assay for monitoring heparin anticoagulation during various medical procedures. The Hemochron Jr. ACT+ test demonstrates a dose response to heparin between and units/mL of blood by time increases relative to the increasing concentrations of heparin. It is intended for use in monitoring moderate to high heparin doses frequently associated with cardiopulmonary bypass surgery and angioplasty. The ACT+ is not as sensitive to very low levels of heparin such as those encountered in critical care. The test is unaffected by aprotinin. The ACT+ test is for in vitro diagnostic use and is for use with any model Hemochron Whole Blood Microcoagulation System.
Principle
The Hemochron Microcoagulation Systems utilize a mechanical endpoint clotting mechanism in which testing occurs within the disposable ACT+ cuvette. Following whole blood sample introduction, the instrument precisely measures 15 microliters of blood and automatically moves it into the test channel within the ACT+ cuvette. The remainder of the blood sample, not needed for testing, is automatically drawn into the waste channel of the cuvette. Test initiation and sample/reagent mixing are performed automatically, requiring no operator interaction. After mixing with the reagent, the sample is